Clifford Stocks
Founder at OncoResponse, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Kieron Jones | M | - |
K2 Biolabs LLC
K2 Biolabs LLC Miscellaneous Commercial ServicesCommercial Services K2 Biolabs LLC is an early-stage life science company that aims to develop the next generation of therapies to improve the lives of patients. The company is based in Houston, TX. K2 Biolabs was founded by Kieron Jones, Andrew L. Strong, and Kevin M. Slawin, with Kieron Jones serving as the CEO since incorporation. | - |
James A. Barlow | M | - |
Immunogenesis, Inc.
Immunogenesis, Inc. Miscellaneous Commercial ServicesCommercial Services Immunogenesis, Inc. develops immunotherapeutic for cold cancers. The company was founded by Michael A. Curran in 2019 and is headquartered in Houston, TX. | - |
Carol Gallagher | M | 59 |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | - |
Kevin M. Slawin | M | 63 |
K2 Biolabs LLC
K2 Biolabs LLC Miscellaneous Commercial ServicesCommercial Services K2 Biolabs LLC is an early-stage life science company that aims to develop the next generation of therapies to improve the lives of patients. The company is based in Houston, TX. K2 Biolabs was founded by Kieron Jones, Andrew L. Strong, and Kevin M. Slawin, with Kieron Jones serving as the CEO since incorporation. | - |
Steven Gillis | M | 71 |
Theraclone Sciences, Inc.
Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA.
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | - |
William Tanner | M | - |
Immunogenesis, Inc.
Immunogenesis, Inc. Miscellaneous Commercial ServicesCommercial Services Immunogenesis, Inc. develops immunotherapeutic for cold cancers. The company was founded by Michael A. Curran in 2019 and is headquartered in Houston, TX. | 5 years |
Wende Hutton | F | 63 |
Theraclone Sciences, Inc.
Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA.
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | - |
Sean McCarthy | M | 57 |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | - |
Andrew L. Strong | M | 57 |
K2 Biolabs LLC
K2 Biolabs LLC Miscellaneous Commercial ServicesCommercial Services K2 Biolabs LLC is an early-stage life science company that aims to develop the next generation of therapies to improve the lives of patients. The company is based in Houston, TX. K2 Biolabs was founded by Kieron Jones, Andrew L. Strong, and Kevin M. Slawin, with Kieron Jones serving as the CEO since incorporation. | - |
Ted Koutouzis | M | - |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA.
Immunogenesis, Inc.
Immunogenesis, Inc. Miscellaneous Commercial ServicesCommercial Services Immunogenesis, Inc. develops immunotherapeutic for cold cancers. The company was founded by Michael A. Curran in 2019 and is headquartered in Houston, TX. | - |
Wendye Robbins | M | 63 |
Theraclone Sciences, Inc.
Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | - |
Roberto de Ponti | M | - |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | 8 years |
Chris Mirabelli | M | 69 |
Theraclone Sciences, Inc.
Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | - |
Andrew W. DeSomma | M | - |
K2 Biolabs LLC
K2 Biolabs LLC Miscellaneous Commercial ServicesCommercial Services K2 Biolabs LLC is an early-stage life science company that aims to develop the next generation of therapies to improve the lives of patients. The company is based in Houston, TX. K2 Biolabs was founded by Kieron Jones, Andrew L. Strong, and Kevin M. Slawin, with Kieron Jones serving as the CEO since incorporation. | - |
John McKearn | M | 70 |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | - |
Robert Stein | M | 73 |
Immunogenesis, Inc.
Immunogenesis, Inc. Miscellaneous Commercial ServicesCommercial Services Immunogenesis, Inc. develops immunotherapeutic for cold cancers. The company was founded by Michael A. Curran in 2019 and is headquartered in Houston, TX. | 5 years |
Robert Stein | M | - |
Immunogenesis, Inc.
Immunogenesis, Inc. Miscellaneous Commercial ServicesCommercial Services Immunogenesis, Inc. develops immunotherapeutic for cold cancers. The company was founded by Michael A. Curran in 2019 and is headquartered in Houston, TX. | 5 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
George B. Rathmann | M | - |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 11 years |
Paul Clark | M | 76 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 8 years |
Kristine Swiderek | M | - |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA.
Theraclone Sciences, Inc.
Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | 7 years |
Christopher Henney | M | 83 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 6 years |
Russell Hawkinson | M | 65 |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA.
Theraclone Sciences, Inc.
Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | 11 years |
Kenneth Ferguson | M | 68 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 17 years |
Gary L. Wilcox | M | 77 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 14 years |
Philip C. Ranker | M | 64 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 3 years |
Bradford Zakes | M | 57 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 4 years |
David Milligan | M | 83 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 12 years |
Mark Lupher | M | 53 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 9 years |
John Brown Kliewer | M | - |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | - |
William D. Welch | M | - |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 5 years |
J. Whitaker | M | 68 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 13 years |
Albert S. Yu | M | 67 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 15 years |
Scott Robert Peterson | M | 62 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 8 years |
Sean W. O'Dea | M | - |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 6 years |
Domingo Rodriguez | M | 62 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 3 years |
Leonard M. Blum | M | 63 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 7 years |
Judith A. Woods | M | 71 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 9 years |
Patrick Joseph Hojlo | M | - |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | - |
Frank T. Cary | M | 103 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | - |
W. Michael Gallatin | M | - |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 15 years |
Robert John Herbold | M | 81 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | - |
Robert W. Pangia | M | 72 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 16 years |
Michael Stein | M | 74 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 6 years |
Teresa Beck | F | 69 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 3 years |
David McElligott | M | - |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | - |
Jeffrey G. Hesselberg | M | 65 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 11 years |
Jun Bao | M | 58 |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 1 years |
Michele K. Yetman | F | - |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 14 years |
David Alan Goodkin | M | - |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 5 years |
Bob Lechleider | M | 63 |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 50 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Clifford Stocks
- Personal Network